• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bigfoot compares trial data with modeling results for automated insulin delivery system

November 7, 2017 By Sarah Faulkner

Bigfoot Biomedical automated insulin delivery systemBigfoot Biomedical touted data last week at this year’s Diabetes Technology Meeting showing that results from a feasibility study evaluating the company’s automated insulin delivery system closely matched data gleaned from prospective modeling.

The company said it conducted extensive modeling to refine the technology’s algorithms prior to the start of its trial in 2016, Bigfoot said. Data collected from simulations closely predicted how Bigfoot’s automated insulin delivery system would perform when tested in a group of diverse patients.

“Bigfoot is heralding the future of artificial intelligence to accelerate the development and testing of drug delivery therapies,” president & CEO Jeffrey Brewer said in prepared remarks. “Our ability to model the physiology of insulin-requiring diabetes allows us to simulate months-long clinical trials consisting of thousands of subjects in mere minutes for a fraction of the cost.”

“People with insulin-requiring diabetes must constantly monitor their blood glucose levels, what and when they eat, and when and how they exercise in order to make calculations and decisions about using insulin,” Lane Desborough, Bigfoot’s chief engineer, added.

“Algorithms for automating insulin delivery must be safe and effective for a diverse group of people and account for significant variations in meals, stress, exercise, and illness. Our innovative virtual clinic provides critical insights into how our technology is anticipated to function in these real-world situations. The agreement between our predicted results and our study data validates and supports our use of modeling and simulation to hone our algorithms and predict clinical outcomes.”

Bigfoot is planning a pivotal trial for its system that is slated to launch in 2018 in the U.S.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Bigfoot Biomedical

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS